> Detailanzeige

Press, Oliver W.; Eary, Janet F.; Gooley, Ted; Gopal, Ajay K.; Liu, Stephen; Rajendran, Joseph G.; Maloney, David G.; Petersdorf, Stephen; Bush, Sharon A.; Durack, Lawrence D.; Martin, Paul J.; Fisher, Darrell R.; Wood, Brent; Borrow, James W.; Porter, Bruce; Smith, Justin P.; Matthews, Dana C.; Appelbaum, Frederick R.; Bernstein, Irwin D.

A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
  • Beteiligte: Press, Oliver W.; Eary, Janet F.; Gooley, Ted; Gopal, Ajay K.; Liu, Stephen; Rajendran, Joseph G.; Maloney, David G.; Petersdorf, Stephen; Bush, Sharon A.; Durack, Lawrence D.; Martin, Paul J.; Fisher, Darrell R.; Wood, Brent; Borrow, James W.; Porter, Bruce; Smith, Justin P.; Matthews, Dana C.; Appelbaum, Frederick R.; Bernstein, Irwin D.
  • Erschienen: American Society of Hematology, 2000
  • Erschienen in: Blood
  • Sprache: Englisch
  • DOI: 10.1182/blood.v96.9.2934
  • ISSN: 1528-0020; 0006-4971
  • Schlagwörter: Cell Biology ; Hematology ; Immunology ; Biochemistry
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:p>Relapsed B-cell lymphomas are incurable with conventional chemotherapy and radiation therapy, although a fraction of patients can be cured with high-dose chemoradiotherapy and autologous stem-cell transplantation (ASCT). We conducted a phase I/II trial to estimate the maximum tolerated dose (MTD) of iodine 131 (131I)–tositumomab (anti-CD20 antibody) that could be combined with etoposide and cyclophosphamide followed by ASCT in patients with relapsed B-cell lymphomas. Fifty-two patients received a trace-labeled infusion of 1.7 mg/kg 131I-tositumomab (185-370 MBq) followed by serial quantitative gamma-camera imaging and estimation of absorbed doses of radiation to tumor sites and normal organs. Ten days later, patients received a therapeutic infusion of 1.7 mg/kg tositumomab labeled with an amount of131I calculated to deliver the target dose of radiation (20-27 Gy) to critical normal organs (liver, kidneys, and lungs). Patients were maintained in radiation isolation until their total-body radioactivity was less than 0.07 mSv/h at 1 m. They were then given etoposide and cyclophosphamide followed by ASCT. The MTD of131I-tositumomab that could be safely combined with 60 mg/kg etoposide and 100 mg/kg cyclophosphamide delivered 25 Gy to critical normal organs. The estimated overall survival (OS) and progression-free survival (PFS) of all treated patients at 2 years was 83% and 68%, respectively. These findings compare favorably with those in a nonrandomized control group of patients who underwent transplantation, external-beam total-body irradiation, and etoposide and cyclophosphamide therapy during the same period (OS of 53% and PFS of 36% at 2 years), even after adjustment for confounding variables in a multivariable analysis.</jats:p>
  • Zugangsstatus: Freier Zugang